Trial Profile
Evaluation of Adherence Rate in Patients Receiving PegIntron [peginterferon alfa-2b]/ Rebetol [ribavirin] (Weight Based) for Hepatitis C in Conjunction With a Patient Assistance Program
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b/ribavirin (Primary) ; Antidepressants; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 19 Aug 2008 New trial record.